Welcome to our dedicated page for Co-Diagnostics SEC filings (Ticker: CODX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the rollout of the Co-Dx PCR platform or gauging demand for Co-Primers鈩� reagents means decoding financial signals buried deep in SEC documents. If you have ever searched for 鈥淐o-Diagnostics quarterly earnings report 10-Q filing鈥� or 鈥淐o-Diagnostics 8-K material events explained,鈥� you know the challenge: dense biotech language, assay-validation footnotes and tables that stretch for pages.
Stock Titan鈥檚 AI turns that complexity into clarity. Our engine parses each sentence of the latest Co-Diagnostics annual report 10-K simplified, highlights revenue tied to infectious-disease kits and links regulatory milestones to real numbers. It also streams Co-Diagnostics Form 4 insider transactions real-time, so you can follow Co-Diagnostics insider trading Form 4 transactions and monitor executive stock transactions Form 4 without refreshing EDGAR. Prefer the quick path? Click 鈥淎I Summary鈥� to get Co-Diagnostics SEC filings explained simply in under a minute, including focused sections on the proxy statement executive compensation and pending product clearances.
Every filing type is one click away:
- 10-Q earnings report filing analysis with segment breakouts
- Instant alerts on Co-Diagnostics 8-K material events
- Understanding Co-Diagnostics SEC documents with AI through plain-language highlights
- Historical archives for research or compliance reviews
Whether you鈥檙e comparing R&D spend quarter over quarter, mapping royalty streams, or timing trades around FDA decisions, our real-time updates and expert commentary keep you ahead. Save hours of manual reading and focus on what matters most inside every Co-Diagnostics filing.
Co-Diagnostics, Inc. (CODX) reported continued operating losses and heavy customer concentration alongside notable cash inflows in the first half of 2025. The company recorded a loss per share of $(0.23) and $(0.25) for the comparable three-month periods and $(0.47) and $(0.56) for the six-month comparatives, with weighted average basic shares around 33.1 million for the most recent quarter. Grant funding dropped to $0 for both the three- and six-month periods ended June 30, 2025, versus $2.5 million and $2.7 million in the prior-year periods. Accounts receivable net balances were $210,968 at June 30, 2025 and $132,570 at December 31, 2024, with two large customers representing a majority of receivables and three customers accounting for roughly 53% of product revenue in the quarter. Cash and liquidity improved: the company reported a $8.18 million net increase in cash and cash equivalents and received net proceeds of $1.02 million from an at-the-market equity program after selling 2,209,131 shares; maturities of marketable securities generated $31.51 million. Inventory totaled $1,084,627 with reserves recorded; the company recognized inventory reserve changes of $59,591 and $101,065 for the three- and six-month periods ended June 30, 2025. Lease obligations include operating lease long-term portion of $879,258 and present value of operating lease liabilities of $1,703,716. Nasdaq notified the company of a bid-price deficiency but CODX is eligible for an additional compliance period and may cure via a reverse split if needed.
FAQ
What is the current stock price of Co-Diagnostics (CODX)?
What is the market cap of Co-Diagnostics (CODX)?
